GenPharm/Lilly
Executive Summary
Will collaborate on development of human monoclonal antibodies to treat cancer. Deal announced Sept. 30 will combine GenPharm's transgenic mice antibody production method with an anti-cancer drug- targeting technology developed by Lilly. GenPharm will receive an undisclosed equity investment by Lilly, as well as research payments and royalties.